<!doctype html> <html> <head><style>
             table { border-collapse: collapse; }
             th, td {
               word-wrap: break-word;
               max-width: 100%;
               font-family: "Trebuchet MS", Arial, Helvetica, sans-serif;
               border-bottom: 1px solid #ddd;
               padding: 5px;
               text-align: left;
             }
            tr:hover {background: #f4f4f4;}
            tr:hover .highlighted {background: repeating-linear-gradient(
                    45deg,
                    #ffff99,
                    #ffff99 10px,
                    #f4f4f4 10px,
                    #f4f4f4 20px
                  );}
           .highlighted { background-color: #ffff99; }
          </style></head><body><h2>The Cancer Genome Atlas</h2><br> <b>Section Title</b>: Publications <br><b>Table Section Text</b>: <i> None </i> <br> <table>
<tr> <th colspan=1 rowspan=1 > Cancer Type Studied </th><th colspan=1 rowspan=1 > Final Number Analyzed in Original Marker Paper </th><th colspan=1 rowspan=1 > Data Publicly Available </th><th colspan=1 rowspan=1 > TCGA Analysis Findings </th></tr>
<tr> <td colspan=1 rowspan=1 > Glioblastoma Multiforme </td><td colspan=1 rowspan=1 > 206 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > GBM subtypes Classical, Mesenchymal and Proneural are defined by EGFR, NF1, and PDGFRA/IDH1 mutations respectively; over 40% of tumors have mutations in chromatin-modifier genes; other frequently mutated genes include TP53, PlK3R1, PIK3CA, IDH1, PTEN, RB1, LZTR1 </td></tr>
<tr> <td colspan=1 rowspan=1 > Lower Grade Glioma </td><td colspan=1 rowspan=1 > 293 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Defined three subtypes correlating with patient outcomes: IDH1 mutant with 1p/19q deletion, IDH mutant without 1p/19q deletion, and IDH wildtype; IDH wildtype is genomically similar to glioblastoma </td></tr>
<tr> <td colspan=1 rowspan=1 > Breast Lobular Carcinoma </td><td colspan=1 rowspan=1 > 203 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Lobular carcinoma distinct from ductal carcinoma; FOXA1 elevated in lobular carcinoma, GATA3 elevated in ductal carcinoma; lobular carcinoma enriched for PTEN loss and Akt activation </td></tr>
<tr> <td colspan=1 rowspan=1 > Breast Ductal Carcinoma </td><td colspan=1 rowspan=1 > 784 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Four distinct genomic subtypes: basal, Her2, luminal A, luminal B; most common driver mutations TP53, PIK3CA, GATA3; basal subtype similar to serous ovarian cancer </td></tr>
<tr> <td colspan=1 rowspan=1 > Colorectal Adenocarcinoma </td><td class="highlighted"  colspan=1 rowspan=1 > 276 </td><td colspan=1 rowspan=1 > X </td><td class="highlighted"  colspan=1 rowspan=1 > Colon and rectal cancers have similar genomic profiles; hypermutated subtype (16% of samples) mostly found in right colon and associated with favorable prognosis; new potential drivers: ARlD1A, SOX9, FAM123B/WTX; overexpression of: ERBB2, IGF2; mutations in the WNT pathway </td></tr>
<tr> <td colspan=1 rowspan=1 > Stomach Adenocarcinoma </td><td colspan=1 rowspan=1 > 295 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Identified four subtypes: EBV characterized by Epstein-Barr virus infection, MSI (microsatellite instability) characterized by hypermutation, GS characterized by genomic stability, CIN characterized by chromosomal instability; CIN enriched for mutations in tyrosine kinases </td></tr>
<tr> <td colspan=1 rowspan=1 > Esophageal Carcinoma </td><td colspan=1 rowspan=1 > 164 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Squamous cell and adenocarcinoma are molecularly distinct; squamous cell carcinomas were similar to head and neck squamous cell carcinomas and had frequent amplifications of CCND1, SOX2 and TP63; adenocarcinomas were similar to chromosomally unstable gastric adenocarcinoma and had frequent amplifications in ERBB2, VEGFA, GATA4, and GATA6 </td></tr>
<tr> <td colspan=1 rowspan=1 > Ovarian Serous Cystadenocarcinoma </td><td colspan=1 rowspan=1 > 489 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Mutations in TP53 occurred in 96% of the cases studied; mutations in BRCA1 and BRCA2 occurred in 21% of the cases and were associated with more favorable outcomes </td></tr>
<tr> <td colspan=1 rowspan=1 > Uterine Corpus Endometrial Carcinoma </td><td colspan=1 rowspan=1 > 373 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Classified endometrial cancers into four categories: POLE ultramutated, MSI (microsatellite instability) hypermutated, copy-number low, and copy-number high; uterine serous carcinomas were similar to ovarian serous and basal-like Breast carcinomas and had less favorable prognoses than uterine endometrioid carcinomas </td></tr>
<tr> <td colspan=1 rowspan=1 > Cervical Squamous Cell Carcinoma and Adenocarcinoma </td><td colspan=1 rowspan=1 > 228 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Identification of HPV-negative, endometrial-like cervical cancers with mutations in KRAS, ARID1A, and PTEN genes; amplification of CD274 and PDCD1LG2 immune checkpoint genes; alterations to genes including MED1, ERBB3, CASP8, HLA-A, and TGFBR2 and fusions involving lncRNA BCAR4; nearly three-quarters of samples had alterations in either one or both of the PI3K/MAPK and TGF-beta signaling pathways </td></tr>
<tr> <td colspan=1 rowspan=1 > Head and Neck Squamous Cell Carcinoma </td><td colspan=1 rowspan=1 > 279 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Identified genomic features of HPV- and smoking-related cancers: HPV-positive characterized by shortened or deleted TRAF3, HPV-negative characterized by co-amplification of 11q13 and 11q22, smoking-related characterized by TP53 mutations, CDKN2A inactivation, and copy number alterations </td></tr>
<tr> <td colspan=1 rowspan=1 > Thyroid Carcinoma </td><td colspan=1 rowspan=1 > 496 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Majority driven by RAS or BRAFV600E mutations; tumors driven by these mutations are distinct </td></tr>
<tr> <td colspan=1 rowspan=1 > Acute Myeloid Leukemia </td><td colspan=1 rowspan=1 > 200 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Low mutation burden, with only 13 coding mutations on average per tumor; classified driver events into nine categories including transcription factor fusions, histone modifier mutations, spliceosome mutations and others </td></tr>
<tr> <td colspan=1 rowspan=1 > Cutaneous Melanoma </td><td colspan=1 rowspan=1 > 331 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Established four subtypes: BRAF mutant, RAS mutant, NF1 mutant, and triple wild-type based on driver mutations; higher levels of immune lymphocyte infiltration correlated with better patient survival </td></tr>
<tr> <td colspan=1 rowspan=1 > Lung Adenocarcinoma </td><td colspan=1 rowspan=1 > 230 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > High mutation burden; 76% of tumors demonstrated activation of receptor tyrosine kinase pathways </td></tr>
<tr> <td colspan=1 rowspan=1 > Lung Squamous Cell Carcinoma </td><td colspan=1 rowspan=1 > 178 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > High average number of mutations and copy number aberrations; like ovarian serous cystadenocarcinoma, almost all lung squamous cell carcinomas contained a mutation in TP53; many tumors contained inactivating mutations in HLA-A that may help the cancer avoid immune detection </td></tr>
<tr> <td colspan=1 rowspan=1 > Clear Cell Renal Cell Carcinoma </td><td colspan=1 rowspan=1 > 446 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Commonly mutated genes included VHL involved in oxygen sensing, SED2 involved in epigenetic modifications resulting in global hypomethylation, and genes of the PI3K/AKT/mTOR pathway; metabolic shift similar to the 'Warburg effect' correlates with a poor prognosis </td></tr>
<tr> <td colspan=1 rowspan=1 > Kidney Papillary Carcinoma </td><td colspan=1 rowspan=1 > 161 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > 81% of type 1 tumors contained an alteration to MET; genomic profiles of type 2 tumors were heterogeneous, with alterations to CDKN2A, SETD2, TFE3, or increased expression of the NRF2–ARE pathway; loss of expression of CDKN2A and CpG island methylation phenotype were associated with poor outcome </td></tr>
<tr> <td colspan=1 rowspan=1 > Invasive Urothelial Bladder Cancer </td><td colspan=1 rowspan=1 > 131 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Smoking is associated with increased risk; frequently mutated genes include TP53, which was inactivated in 76% of tumors and ERBB2 (HER2), genes in the receptor tyrosine kinase (RTK)/RAS pathways altered in 44% of tumors; </td></tr>
<tr> <td colspan=1 rowspan=1 > Prostate Adenocarcinoma </td><td colspan=1 rowspan=1 > 333 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Highly heterogeneous with 26% of samples driven by unknown molecular alterations; 7 subtypes defined by ETS transcription factor gene fusions or mutations in SPOP, FOXA1, or IDH1; actionable lesions in the PI3K, MAPK, and DNA repair pathways </td></tr>
<tr> <td colspan=1 rowspan=1 > Chromophobe Renal Cell Carcinoma </td><td colspan=1 rowspan=1 > 66 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Extremely low mutation burden; the carcinoma originates from more distal regions of the kidney compared to clear cell carcinoma, which is primarily from proximal regions; metabolic shift distinct from the 'Warburg effect' shift observed in clear cell carcinoma; TP53 and PTEN tumor suppressor genes were frequently mutated; TERT gene promoter was frequently altered </td></tr>
<tr> <td colspan=1 rowspan=1 > Adrenocortical Carcinoma </td><td colspan=1 rowspan=1 > 91 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Overexpression of IGF2, mutations in TP53, PRKAR1A and other genes, and copy number alterations were common hallmarks; hypoploidy followed by whole genome doubling may be a driving mechanism of tumor development </td></tr>
<tr> <td colspan=1 rowspan=1 > Paraganglioma & Pheochromocytoma </td><td colspan=1 rowspan=1 > 173 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Four distinct subtypes: Wnt-altered, cortical admixture, pseudohypoxia and kinase signaling; MAML3 fusion gene and CSDE1 somatic mutation define and drive the poor prognosis, Wnt-altered subtype </td></tr>
<tr> <td colspan=1 rowspan=1 > Cholangiocarcinoma </td><td colspan=1 rowspan=1 > 38 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Low expression of CDKN2, BAP1, and ARID1 genes and overexpression of FGFR2 and IDH1/2 genes; four subtypes, one subtype characterized by alterations in IDH, silencing of ARID1A and low expression of other chromatin modifiers, and high mitochondrial gene expression; another subtype characterized by BAP1 mutations and FGFR2 gene fusions; the cancer may exist on a continuous spectrum with a subset of liver carcinomas with IDH or FGFR mutations </td></tr>
<tr> <td colspan=1 rowspan=1 > Liver Hepatocellular Carcinoma </td><td colspan=1 rowspan=1 > 363 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > TERT promoter mutations, identified in 44% of tumors, associated with increased elongation of telomeres and silencing of CDKN2A; TP53 commonly mutated or under-expressed; CTNNBB1 significantly mutated; many tumors with high levels of lymphocyte infiltration or overexpressed immune checkpoint genes CTLA4, PD-1, and PD-L1 </td></tr>
<tr> <td colspan=1 rowspan=1 > Pancreatic Ductal Adenocarcinoma </td><td colspan=1 rowspan=1 > 150 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Used deep and targeted sequencing to better analyze low neoplastic cellularity; KRAS mutations present in 93% of tumors; mutations in RREB1 or other members of RAS-MAPK signaling pathway </td></tr>
<tr> <td colspan=1 rowspan=1 > Uterine Carcinosarcoma </td><td colspan=1 rowspan=1 > 57 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Identified a strong and varied degree of epithelial-mesenchymal transition; TP53 mutations present in 91% of samples; alterations in PI3K present in half of samples </td></tr>
<tr> <td colspan=1 rowspan=1 > Uveal Melanoma </td><td colspan=1 rowspan=1 > 80 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > Complex mutations in BAP1; identified distinct subdivisions of disomy 3 (D3) and monosomy 3 (M3) subtypes; in M3, mutually exclusive EIF1AX and SRSF2/SF3B1 mutations have distinct methylation profiles and prognoses </td></tr>
<tr> <td colspan=1 rowspan=1 > Thymoma </td><td colspan=1 rowspan=1 > 124 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 >  </td></tr>
<tr> <td colspan=1 rowspan=1 > Sarcoma </td><td colspan=1 rowspan=1 > 206 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 > TP53, ATRX, and RB1 among the few genes recurrently mutated across sarcoma types; copy number alterations frequently occurred in complex karyotype sarcomas, affecting p53 and RB1 cell cycle and other pathways; synovial sarcoma sarcomas expressed fusions in SSX1 or SSX2 and TERT; For dedifferentiated liposarcoma, JUN amplification associates with worse survival; altered PI3K-AKT-mTOR pathway in leiomyosarcoma; undifferentiated pleomorphic sarcoma and myxofibrosarcoma may be driven by alterations in the Hippo pathway </td></tr>
<tr> <td colspan=1 rowspan=1 > Mesothelioma </td><td colspan=1 rowspan=1 > 87 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 >  </td></tr>
<tr> <td colspan=1 rowspan=1 > Testicular Germ Cell Cancer </td><td colspan=1 rowspan=1 > 150 </td><td colspan=1 rowspan=1 > X </td><td colspan=1 rowspan=1 >  </td></tr>
</table> <br> <h3>Sentence(s)</h3>1. TCGA analyzed 276 samples of colon and rectal cancers. <br> <br><br><b>Categories:</b><br><b>Numerical:</b> Uses math skills for writing the sentence. Uses math operations (addition, subtraction, average, etc.), counting numbers, frequency of items, etc.<br> <b>Commonsense:</b> Uses commonsene knowledge about situations humans encounter in everyday life – physical objects, word meanings, social or physical domains, peoples' intentions, etc.<br> <b>Temporal:</b> When concepts related to time and temporal aspects are required for writing the sentence. Duration, ordering, typical time of events, time differences between events.<br> <b>Table:</b> Writing the sentence requires knowledge from the table except: the highlighted cells, row and column headers, table titles, section titles, section texts.<br> <b>Out of Table:</b> Writing the sentence requires external knowledge that is not present in the table nor common sense. Knowledge about some specific domain comes under this category. </body></html>
